A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999.
Progressive disease or end of study
Charles W. Finn, PhD
Symphony Evolution, Inc.
United States: Food and Drug Administration
|Hematology Oncology Associates of Rockland Union State Bank Cancer Center||Nyack, New York 10960|
|University of Texas Cancer Center||San Antonio, Texas 78229|